 |
 |
Date Announced: 12 Nov 2012
Medical laser firm may use cash to fund acquisitions.
WESTFORD, Mass., Nov. 12, 2012 /PRNewswire/ -- Cynosure, Inc. (CYNO) (the "Company"), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that it has commenced an underwritten registered public offering of 2,600,000 shares of its class A common stock. In addition, El.En. S.p.A. is offering 600,000 shares of the Company's class A common stock.
Leerink Swann LLC, the underwriter for this offering, has the option for a period of up to 30 days from the date of the prospectus supplement to purchase up to an additional 240,000 shares from the Company and up to an additional 240,000 shares from El.En. S.p.A. at the public offering price less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.
The Company intends to use the net proceeds from the shares sold by it in this offering for general corporate purposes and to fund its potential acquisition of complementary products, technologies or businesses. The Company will not receive any proceeds from the sale of the shares by El.En. S.p.A.
The shares are being offered by the Company pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC") and declared effective on October 26, 2012. A preliminary prospectus supplement and accompanying base prospectus related to the offering will be filed with the SEC and available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by calling (800) 808-7525.
Source: Cynosure
E-mail: via web site
Web Site: www.cynosure.com
| © 2024 SPIE Europe |
|
